MedTrace Logo

TO-ChERIsH: Trajectory of Cardiovascular Ageing, Its Determinants and Impact on Health

NCT04501562 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2025-06-05

No results posted yet for this study

Summary

Specific Aim 1: To determine longitudinal changes in CV ageing (changes in CV imaging) over time.

Hypothesis: There are differences in rates of CV ageing over time.

Specific Aim 2: To study determinants of CV ageing To assess how biological pathways affect CV ageing by studying the relationships between biological signatures measured in longitudinal biospecimens are associated with CV ageing.

Hypothesis: Antecedent biological markers are associated with progression of CV ageing.

Specific Aim 3: To determine the impact of CV ageing progression on the development of clinical CVD and the overall physical, cognitive and functional health of the elderly.

Hypothesis: Those with stable CV imaging phenotypes have lower incidence of clinical CVD and also better overall health in ageing, compared to those with rapid deterioration (unhealthy CV ageing).

Conditions

  • Cardiac Ageing

Interventions

OTHER

Examinations

Participants will undergo focused examinations that include measurement of height, weight, waist circumference, body composition analysis, baseline data collection and blood pressure examinations. Resting electrocardiography will be performed to ascertain sinus rhythm.

OTHER

Cardiovascular Tests

Specific quantitative cardiac ageing-related outcome parameters will be examined by multimodal techniques including two-dimensional transthoracic echocardiogram, and/or non-contrast magnetic resonance imaging/magnetic resonance spectroscopy.

OTHER

Bio-specimen collection

Bio-specimens collected will include fresh blood, urine and/or stool specimens.

OTHER

Clinical/health outcome collection

Health status will be tracked by telephone follow-up and/or matching at national disease registries at periodic intervals within one to five years, up to three decades.

Sponsors & Collaborators

  • National Heart Centre Singapore

    lead OTHER

Principal Investigators

  • Angela Koh, M.D. · National Heart Centre Singapore

Eligibility

Min Age
21 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-13
Primary Completion
2049-12-31
Completion
2049-12-31

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04501562 on ClinicalTrials.gov